BRAF Inhibitors and Melanoma

Abstract excerpt

Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable. An overall survival benefit has been established for them, BRAF in it,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Melanoma and MAPK Pathways